WallStreetZenWallStreetZen

NASDAQ: CSBR
Champions Oncology Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Champions Oncology revenue was $58.59M for the trailing 12 months ending Jan 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Jan 31, 2025 was $17.0M, up 26.3% from last quarter. For the last reported fiscal year 2024 ending Apr 30, 2024, CSBR annual revenue was $50.2M, with -6.9% growth year-over-year.

CSBR past revenue growth

How has CSBR's revenue growth performed historically?

Company
19.03%
Industry
474.99%
Market
20.88%
CSBR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CSBR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CSBR's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CSBR revenue history

Current Revenue
$58.6M
Current Earnings
$6.4M
Current Profit Margin
11%

Be the first to know when CSBR announces revenue.

CSBR Revenue History By Year

CSBR Yearly RevenueCSBR RevenueCSBR ChangeCSBR Revenue Growth
2024-04-30$50.16M-$3.72M-6.90%
2023-04-30$53.87M$4.76M+9.69%
2022-04-30$49.11M$8.07M+19.66%
2021-04-30$41.04M$8.92M+27.76%
2020-04-30$32.12M$5.06M+18.68%
2019-04-30$27.07M$6.83M+33.72%
2018-04-30$20.24M$4.83M+31.34%
2017-04-30$15.41M$4.23M+37.82%
2016-04-30$11.18M$2.32M+26.16%
2015-04-30$8.86M-$2.69M-23.26%
2014-04-30$11.55M$3.23M+38.77%
2013-04-30$8.32M$1.17M+16.42%
2012-04-30$7.15M$267.00k+3.88%
2011-04-30$6.88M$1.99M+40.65%
2010-04-30$4.89M$1.18M+31.89%
2009-04-30$3.71M$2.31M+165.00%
2008-04-30$1.40MN/AN/A
2007-04-30$0.00N/AN/A
2006-04-30$0.00N/AN/A

1 of 2

Champions Oncology Revenue FAQ

What was CSBR's revenue last quarter?

On Invalid Date, Champions Oncology (NASDAQ: CSBR) reported Q4 2024 revenue of $17.04 million up 41.77% year over year. In the same quarter last year, Champions Oncology's revenue was $12.02 million.

What was Champions Oncology's revenue in 2024?

Champions Oncology's annual revenue for the twelve months ending Apr 30, 2024 was $50.16 million, a 6.9% decrease year over year.

How much does Champions Oncology make in a day?

Based on Champions Oncology annual revenue for the past five years, CSBR makes an average of $123,998.36 per day.

What was Champions Oncology's annual revenue growth in the past year?

As of Q2 2025, Champions Oncology's revenue has grown 19.03% year over year. This is 455.96 percentage points lower than the US Biotechnology industry revenue growth rate of 474.99%. Champions Oncology's revenue in the past year totaled $58.59 million.

How much does Champions Oncology make in a year?

Champions Oncology's revenue by year for the past five years is:
  • Champions Oncology's revenue for the twelve months ending Apr 30, 2024 was $50.16 million, a 6.9% decrease year over year.
  • Champions Oncology's annual revenue for Apr 30, 2023 was $53.87 million, a 9.69% increase from 2022.
  • Champions Oncology's annual revenue for 2022 was $49.11 million, a 19.66% increase from 2021.
  • Champions Oncology's annual revenue for 2021 was $41.04 million, a 27.76% increase from 2020.
  • Champions Oncology's annual revenue for 2020 was $32.12 million, a 18.68% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.